Related Experiment Video

Updated: Jun 25, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Chemokine receptors as targets for cancer therapy

Xuesong Wu1, Vivian C Lee, Eric Chevalier

  • 1Department of Dermatology - Froedtert Clinics, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI 53226, USA.

Current Pharmaceutical Design
|March 12, 2009
PubMed

Insights

Chemokine receptors (CKRs) influence cancer growth and metastasis. Targeting these receptors, particularly CXCR4, shows promise in preclinical models, offering new therapeutic strategies for cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Chemokines and their receptors (CKRs) are crucial for leukocyte trafficking in inflammation.
  • Emerging research highlights the roles of specific CKRs (CXCR4, CCR4, CCR7, CCR10) in cancer progression, metastasis, angiogenesis, and the tumor microenvironment.

Purpose of the Study:

  • To review the multifaceted roles of CKRs in cancer biology.
  • To discuss the potential of CKR antagonists as cancer therapeutics.
  • To identify challenges and future directions in CKR-targeted cancer therapy.

Main Methods:

  • Review of preclinical cancer models investigating CKR function.
  • Analysis of high-throughput screening methods for CKR antagonist discovery.
  • Examination of clinical data and challenges associated with CKR antagonist development.

Main Results:

  • Preclinical data demonstrate that CXCR4 antagonists can inhibit cancer growth by direct action or by modulating the tumor stroma.
  • Despite developed screening methods, challenges in specificity, potency, and drug delivery hinder clinical translation of CKR antagonists.
  • The success of a CCR5 antagonist in HIV treatment suggests potential for other CKR antagonists.

Conclusions:

  • CKRs play significant roles in cancer cell survival and progression.
  • Targeting CKRs, especially CXCR4, presents a promising therapeutic avenue.
  • Combining CKR antagonists with chemotherapy or immunotherapy may enhance cancer treatment specificity and reduce side effects, warranting further investigation into CKR signaling pathways.

More Related Videos

In Vitro Assay to Study Tumor-macrophage Interaction08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...